Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

Sanofi has discontinued its STAT6 degrader SAR448272 program with Nurix just two months after starting clinical trials, amid a broader pipeline restructuring under new CEO Belén Garijo. Nurix remains financially stable with multiple other clinical-stage programs ongoing.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your immunology drug development plans must adapt now that Sanofi has ended its STAT6 degrader trial, revealing shifting priorities at a major pharma partner. This change opens space for you to approach abandoned protein degrader targets in inflammatory disease.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechdrug-developmentpartnershipclinical-trialsbiotechpharmapipeline-restructuring